Financial focus

Nestlé buys Louisiana depression food firm

Nestlé buys Louisiana depression food firm

By Shane STARLING

Nestlé has bought its second brain health-focused medical foods start-up in eight months after snaffling Red River Pharma-owned Pamlab which makes high-dose vitamin supplements targeting depression, diabetes and Alzheimer’s.

How high can high-end omega-3 go?

Special edition: Omega-3 (Editor's blog)

How high can high-end omega-3 go?

By Shane STARLING

Just got off the phone to Ola Snove, the new(ish) CEO of Aker part-owned Norwegian omega-3 specialist Epax. Wanted to know his view on high-end omega-3 prospects that have attracted BASF and DSM to the sector. His word: “Stellar”.

Evolva will reduce the cost of its new yeast-derived resveratrol, it says

Evolva pays €550,000 for Fluxome resveratrol business

By Shane Starling

Swiss biotech firm Evolva has bought failing Fluxome’s, yeast-derived resveratrol business for about €550,000 in cash and shares, but says it has no interest in the remaining omega-3 business being sold by sealed auction.

Schiff MegaRed krill supplement marketing

Reckitt Benckiser-Schiff: Another giant jumps into nutra space

By Shane STARLING

UK-based consumer goods firm Reckitt Benckiser told NutraIngredients today, “nutrition had been on its radar for awhile”, as it plunged $1.4bn (€1.09bn) to outbid German pharma firm Bayer for the US’s second biggest dietary supplements firm, Schiff Nutrition...

Fortitech: Sold to DSM for €495m. Don't expect more of these kinds of buys from DSM in the near future

DSM buys Fortitech for €495m; “We are done for awhile”

By Shane Starling

Rampant nutrition business acquirer, Royal DSM, has splashed the cash for the ninth time in two years – this time to the tune of €495m ($634m) on US-based multinational nutrient blending giant, Fortitech (€212m/$270m annual turnover).

Q3 wrap: Nutrition stars for DSM and Naturex

Q3 wrap: Nutrition stars for DSM and Naturex

By Shane Starling

Royal DSM saw Q3 sales slip 7% to €2.3bn across all divisions with polymer intermediates performing worst, but as has been the case in recent quarters, the Dutch firm’s nutrition cluster held firm with 1% organic growth in difficult economic times.

Follow us

Products

View more

Webinars